169 related articles for article (PubMed ID: 27745798)
61. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
Goeppert B; Folseraas T; Roessler S; Kloor M; Volckmar AL; Endris V; Buchhalter I; Stenzinger A; Grzyb K; Grimsrud MM; Gornicka B; von Seth E; Reynolds GM; Franke A; Gotthardt DN; Mehrabi A; Cheung A; Verheij J; Arola J; Mäkisalo H; Eide TJ; Weidemann S; Cheville JC; Mazza G; Hirschfield GM; Ponsioen CY; Bergquist A; Milkiewicz P; Lazaridis KN; Schramm C; Manns MP; Färkkilä M; Vogel A; ; Boberg KM; Schirmacher P; Karlsen TH
Hepatology; 2020 Oct; 72(4):1253-1266. PubMed ID: 31925805
[TBL] [Abstract][Full Text] [Related]
62. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.
Fujimoto A; Furuta M; Shiraishi Y; Gotoh K; Kawakami Y; Arihiro K; Nakamura T; Ueno M; Ariizumi S; Nguyen HH; Shigemizu D; Abe T; Boroevich KA; Nakano K; Sasaki A; Kitada R; Maejima K; Yamamoto Y; Tanaka H; Shibuya T; Shibata T; Ojima H; Shimada K; Hayami S; Shigekawa Y; Aikata H; Ohdan H; Marubashi S; Yamada T; Kubo M; Hirano S; Ishikawa O; Yamamoto M; Yamaue H; Chayama K; Miyano S; Tsunoda T; Nakagawa H
Nat Commun; 2015 Jan; 6():6120. PubMed ID: 25636086
[TBL] [Abstract][Full Text] [Related]
63. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.
O'Dell MR; Huang JL; Whitney-Miller CL; Deshpande V; Rothberg P; Grose V; Rossi RM; Zhu AX; Land H; Bardeesy N; Hezel AF
Cancer Res; 2012 Mar; 72(6):1557-67. PubMed ID: 22266220
[TBL] [Abstract][Full Text] [Related]
64. Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma.
Wang J; Shi Y; Chen J; Liu J; Zhao X; Pang J; Sun X; Tian Y; Ou Q; Xia F; Chen Y
Cancer Biol Ther; 2023 Dec; 24(1):2223375. PubMed ID: 37337460
[TBL] [Abstract][Full Text] [Related]
65. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.
Nakagawa H; Suzuki N; Hirata Y; Hikiba Y; Hayakawa Y; Kinoshita H; Ihara S; Uchino K; Nishikawa Y; Ijichi H; Otsuka M; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Tateishi K; Koike K
Proc Natl Acad Sci U S A; 2017 May; 114(19):E3806-E3815. PubMed ID: 28439013
[TBL] [Abstract][Full Text] [Related]
66. No Tissue Expression of KRAS or BRAF Mutations in 61 Adult Patients Treated for Esophageal Atresia in Early Childhood.
Dang KX; Ho T; Sistonen S; Koivusalo A; Pakarinen M; Rintala R; Stenman UH; Orpana A; Stenman J
Eur J Pediatr Surg; 2018 Oct; 28(5):413-419. PubMed ID: 28873491
[TBL] [Abstract][Full Text] [Related]
67. The V599E BRAF mutation is uncommon in biliary tract cancers.
Goldenberg D; Rosenbaum E; Argani P; Wistuba II; Sidransky D; Thuluvath PJ; Hidalgo M; Califano J; Maitra A
Mod Pathol; 2004 Nov; 17(11):1386-91. PubMed ID: 15181454
[TBL] [Abstract][Full Text] [Related]
68. KRAS mutation in biliary tract cholangiocarcinoma.
Yasri S; Wiwanitkit V
J Formos Med Assoc; 2017 Mar; 116(3):214. PubMed ID: 28007466
[No Abstract] [Full Text] [Related]
69. Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma.
Liu TT; You HL; Weng SW; Wei YC; Eng HL; Huang WT
PLoS One; 2015; 10(12):e0145388. PubMed ID: 26684807
[TBL] [Abstract][Full Text] [Related]
70. Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma.
Procopio F; Branciforte B; Nappo G; Di Tommaso L; Lleo A; Torzilli G
Eur J Surg Oncol; 2022 Jul; 48(7):1455-1463. PubMed ID: 35317947
[TBL] [Abstract][Full Text] [Related]
71. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
72. L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating
Kim H; Hwang H; Lee H; Hong HJ
Mol Cells; 2017 May; 40(5):363-370. PubMed ID: 28535665
[TBL] [Abstract][Full Text] [Related]
73. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
[TBL] [Abstract][Full Text] [Related]
74. De novo somatic mutations and KRAS amplification are associated with cholangiocarcinoma in a patient with a history of choledochal cyst.
Schwab ME; Song H; Mattis A; Phelps A; Vu LT; Huang FW; Nijagal A
J Pediatr Surg; 2020 Dec; 55(12):2657-2661. PubMed ID: 32295706
[TBL] [Abstract][Full Text] [Related]
75. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
[TBL] [Abstract][Full Text] [Related]
76. KRAS Allelic Variants in Biliary Tract Cancers.
Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
[TBL] [Abstract][Full Text] [Related]
77. Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report.
Eso Y; Uza N; Yamagishi H; Imada K; Kimura Y; Masui T; Kodama Y; Seno H
Medicine (Baltimore); 2017 Dec; 96(50):e9217. PubMed ID: 29390348
[TBL] [Abstract][Full Text] [Related]
78. ELISA-based Ki-ras gene mutation analyses in pancreatic and cholangiocarcinoma cells and tissues.
Gabriel M; Henne-Bruns D; Kalthoff H
Oncol Rep; 2001; 8(6):1367-70. PubMed ID: 11605068
[TBL] [Abstract][Full Text] [Related]
79. Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in
Lim HC; Montesion M; Botton T; Collisson EA; Umetsu SE; Behr SC; Gordan JD; Stephens PJ; Kelley RK
Oncologist; 2018 Sep; 23(9):998-1003. PubMed ID: 29622700
[TBL] [Abstract][Full Text] [Related]
80. Immune checkpoint inhibitor-related molecular markers predict prognosis in extrahepatic cholangiocarcinoma.
Jin B; Wang Y; Zhang B; Xu H; Lu X; Sang X; Wang W; Mao Y; Chen P; Wang S; Qian Z; Wang Y; Du S
Cancer Med; 2023 Oct; 12(20):20470-20481. PubMed ID: 37814942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
